Ty-Jour T1 - 心脏结节病：皮质类固醇和免疫抑制治疗的文献系统审查JF - 欧洲呼吸期刊Jo - Eur Respir J Do - 10.1183 / 13993003 - 2100449-2021 SP - 2100449 Au - Stievenart，Julien Au - Le Guenno，Guillaume Au -Raivard，Marc Au - Rieu，Virieu，Aug - André，Marc Au - Grobost，Vincent Y1 - 2021/01/01/01/1393/26/13993003.00449-2021。抽象N2 - 背景心脏结节病（CS）是一种危及危及危及生命的条件，其中缺乏明确的建议。我们旨在系统地审查皮质类固醇和/或免疫抑制剂治疗的心脏结节病的文献，以便使用PubMed，Embase和Cochrane库数据库更新CS.Method的管理，我们发现了关于皮质类固醇和/或标准免疫抑制疗法的原始文章CS提供至少公平的符号整体评估质量并分析复发率，主要心脏不良事件（拟人）和不良事件。我们将我们的方法基于Prisma陈述和清单。我们检索了21项研究。标志评估提供的平均质量为6.8 / 14（范围5-9）。皮质类固醇似乎对左心室功能，房室梗阻和心间度进行正面影响。仅针对皮质类固醇单独，九种（45％）的研究（n = 351）提供了复发的数据，代表了34％的发病率（n = 119）。三项研究（14％，N = 73）提供了关于甘蓝次（n = 33）的数据，其单独由皮质类固醇治疗的患者中的45％次数。九种研究提供了关于辅助免疫抑制治疗的数据，其中四项研究（n = 78）提供了CS复发数据，其发病率为33％（n = 26）。 Limitations consisted in no randomised control trial retrieved and unclear data on MACEs in patients treated by combined immunosuppressive agents and corticosteroids.Conclusions Corticosteroids should be started early after diagnosis but the exact scheme is still unclear. Studies concerning adjunctive conventional immunosuppressive therapies are lacking and benefits of adjunctive immunosuppressive therapies are unclear. Homogenous data on CS long-term outcomes under corticosteroids, immunosuppressive therapies and other adjunctive therapies are lacking.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. STIEVENART has nothing to disclose.Conflict of interest: Dr. Le Guenno has nothing to disclose.Conflict of interest: Dr. RUIVARD has nothing to disclose.Conflict of interest: Dr. RIEU has nothing to disclose.Conflict of interest: Dr. ANDRE has nothing to disclose.Conflict of interest: Dr. vincent has nothing to disclose. ER -